U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07148089) titled 'A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)' on Aug. 22.
Brief Summary: This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participants with catecholaminergic polymorphic ventricular tachycardia (CPVT). The first-in-human (FIH) safety study will focus on obtaining safety data in adult participants. Cohort 1 and Cohort 2 (optional for dose exploration) will include participants >= 18 years of age. Cohort 3 will include participants >= 7 to < 18 years of age and will be initiated follow...